Trimel Pharmaceuticals
Mississauga
About Trimel Pharmaceuticals
Trimel Pharmaceuticals Corporation, a specialty pharmaceutical company, engages in developing medications for male hypogonadism, female sexual dysfunction, and various respiratory disorders. Its product pipeline includes CompleoTRT, a bioadhesive intranasal gel formulation of testosterone, which has completed Phase III clinical study for treating male hypogonadism; Tefina, an intranasal low-dose gel formulation of testosterone, which is in Phase II clinical study for treating female sexual dysfunction; TBS-3, an intranasal gel formulation of dopamine that has completed a preclinical study for the treatment of Parkinson’s disease; and TBS-7 for the prevention and treatment of asthma symptoms. Its products also include TBS-5, which is in the formulation development stage for the long-term treatment of airway inflammation caused by asthma; and TBS-6, which is in the early-stage exploratory development stage for the treatment of allergic rhinitis. The company was founded in 2008 and is headquartered in Mississauga, Canada.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $69.9M
- Funding stage: IPO
- Last round: Post-IPO Equity (Mar 2019)
- Ticker: tsx:TRL
- Website: trimelpharmaceuticals.com
- Phone: 416-679-0771
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/trimel-pharmaceuticals-2221144 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.